| The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure. | |
| | |
MedLine Citation:
|
PMID: 9330130 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Propionyl-L-carnitine (PLC) is a naturally occurring compound that has been considered for the treatment of congestive heart failure (CHF). The rationale for its use in this pathology is related to its effects on cardiac and skeletal muscle. Chronic treatment with PLC improves the contraction of isolated and aerobic perfused rabbit hearts. The compound improves energy metabolism and myocardial contractility in different experimental models of heart failure, such as pressure-overloaded rats, infarct model of heart failure, and rabbit with streptozotocin-induced diabetes. In general, the effect of PLC is apparent in situations of high energy demand such as those induced by increased workload. It therefore seems likely that PLC is able to correct some metabolic steps of the process that leads to heart failure. In addition, PLC may be helpful in heart failure because of its specific action on peripheral skeletal muscle. Administration of PLC in patients with CHF improves skeletal muscle metabolism by increasing pyruvate flux into the Krebs cycle and by decreasing lactate production. These effects occur in the absence of major hemodynamic and neuroendocrinologic changes and may underlie the ability of PLC to increase exercise performance in patients with heart failure. In a randomized study of 50 patients with mild CHF, PLC increased the maximal exercise time, reduced lactate production, and improved left ventricular ejection fraction. There have been two large-scale trials on the effects of PLC on both cardiac and peripheral muscle function in CHF. One is ongoing; the other one, which just ended, failed to show an improvement in exercise capacity in the population studied. A benefit was evident only in a subgroup of patients with preserved ejection fraction and impaired baseline exercise duration. |
| | |
Authors:
|
R Ferrari; F De Giuli |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Journal of cardiac failure Volume: 3 ISSN: 1071-9164 ISO Abbreviation: J. Card. Fail. Publication Date: 1997 Sep |
Date Detail:
|
Created Date: 1997-11-14 Completed Date: 1997-11-14 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9442138 Medline TA: J Card Fail Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 217-24 Citation Subset: IM |
Affiliation:
|
Chair of Cardiology, University of Brescia, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cardiotonic Agents / pharmacology, therapeutic use* Carnitine / analogs & derivatives*, pharmacology, therapeutic use Chronic Disease Disease Models, Animal Heart / drug effects Heart Failure / drug therapy* Humans Models, Biological Muscles / drug effects Rabbits Rats |
| Chemical | |
Reg. No./Substance:
|
0/Cardiotonic Agents; 17298-37-2/propionylcarnitine; 541-15-1/Carnitine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Myocardial reactive hyperemia in experimental chronic heart failure: evidence for the role of K+ ade...
Next Document: Arthroscopic diagnosis of intra-articular soft tissue injuries associated with distal radial fractur...